FIELD: biotechnology.
SUBSTANCE: invention relates to the production of antitumor fusion proteins, and can be used in medicine for the treatment of melanoma. The following is provided: a three-component fusion protein that is capable of binding i) PD-L1, ii) CXCR4 and iii) Fc receptor and in which component A is linked to component B and component B is linked to component C via disulphide bonds.
EFFECT: invention provides the production of a fusion protein with the possibility of multipoint molecular attachment to lead to the death, immobilization and removal of a tumour cell.
7 cl, 27 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR CULTURING REGULATORY T-CELLS AND ITS APPLICATION | 2020 |
|
RU2807802C1 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| IMMUNOMODULATORY FUSED PROTEINS AND THEIR APPLICATION METHODS | 2016 |
|
RU2755227C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| RECOMBINANT PROTEINS WITH CCN DOMAINS AND FUSION PROTEINS | 2020 |
|
RU2825102C2 |
| COMPOSITION FOR CULTURING NATURAL KILLER CELLS AND METHOD OF PRODUCING NATURAL KILLER CELLS USING SAME | 2020 |
|
RU2824216C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
| THERAPEUTIC FUSION PROTEINS | 2020 |
|
RU2825292C1 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
